Dermapharm Holding SE (0A5J) Financial Statements
Dermapharm Holding SE Financial Overview
Dermapharm Holding SE's market cap is currently $1.91B. The company's EPS TTM is $2.77; its P/E ratio is 13.92; and it has a dividend yield of 2.27%. Dermapharm Holding SE has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.16B | $ 1.18B | $ 1.14B | $ 1.02B | $ 942.91M |
| Gross Profit | $ 391.71M | $ 767.07M | $ 719.16M | $ 660.83M | $ 620.69M |
| Operating Income | $ 221.75M | $ 216.93M | $ 182.89M | $ 243.69M | $ 298.47M |
| EBITDA | $ 314.31M | $ 317.20M | $ 265.55M | $ 329.81M | $ 356.97M |
| Net Income | $ 132.41M | $ 113.79M | $ 62.37M | $ 134.24M | $ 209.58M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 203.41M | $ 121.71M | $ 159.54M | $ 161.36M | $ 172.06M |
| Total Assets | $ 2.20B | $ 2.08B | $ 2.16B | $ 1.41B | $ 1.41B |
| Total Debt | $ 1.05B | $ 979.61M | $ 1.08B | $ 516.45M | $ 580.30M |
| Net Debt | $ 848.88M | $ 858.42M | $ 921.66M | $ 366.53M | $ 419.98M |
| Total Liabilities | $ 1.50B | $ 1.47B | $ 1.62B | $ 880.34M | $ 907.13M |
| Stockholders' Equity | $ 694.38M | $ 604.42M | $ 539.21M | $ 531.59M | $ 497.32M |
| Cash Flow | |||||
| Free Cash Flow | $ 139.39M | $ 163.14M | $ 177.88M | $ 249.52M | $ 189.16M |
| Operating Cash Flow | $ 181.51M | $ 201.38M | $ 219.42M | $ 288.53M | $ 250.37M |
| Investing Cash Flow | $ -110.03M | $ -29.61M | $ -415.43M | $ -99.01M | $ -129.35M |
| Financing Cash Flow | $ 13.32M | $ -209.17M | $ 204.54M | $ -199.77M | $ -80.98M |
Currency in EUR
